Abstract

ObjectiveTo describe trends in the prevalence of diabetes among hospitalized HIV-infected patients between 1997 and 2012 in Spain and compare them with those of age- and sex-matched non–HIV-infected patients.MethodsThe study was based on Spanish national hospital discharge data. We performed a retrospective study for the period 1997–2012. HIV infection (HIV-infected versus non–HIV-infected [control group])and calendar period in relation to widespread use of combination antiretroviral therapy (cART) (1997–1999; 2000–2003; 2004–2007 and 2008–2012), were the exposure variables The outcome variables were diagnosis of diabetes and in-hospital mortality (IHM).ResultsFrom 1997 to 2012, we identified 91,752 cases of diabetes: 15,398 in the HIV-infected group (403,277 hospital admissions) and 76,354 in the non–HIV-infected group (1,503,467 hospital admissions). Overall, HIV-infected patients had lower prevalence values for diabetes than non–HIV-infected patients throughout the follow-up (3.8% vs. 5.1%; p<0.001). The prevalence of diabetes increased 1.56-fold among non–HIV-infected patients and 4.2-fold among HIV-infected patients. The prevalence of diabetes in females was almost twice as high in HIV-infected patients as in non–HIV-infected patients during the last study period (4.72% vs. 2.88%; p<0.001). Diabetes showed a protective effect against IHM throughout the study period (aOR = 0.70; 95%CI, 0.65–0.75).ConclusionsDuring the cART era, the prevalence of diabetes has increased sharply among HIV-infected hospitalized patients compared with matched non–HIV-infected subjects. The prevalence of diabetes is rising very fast among HIV-infected women. Diabetes has a protective effect on IHM among HIV-infected patients. Nevertheless, our study has several limitations. No information is available in the database used on important sociodemographic characteristics and relevant clinical variables including duration of the HIV infection, treatments used, drug resistance, treatment adherence or CD4 count, among others. Also, it is possible that increase of diabetes prevalence could reflect the improvement in recording habits.

Highlights

  • HIV treatment has improved substantially since the introduction of combination antiretroviral therapy

  • Diabetes showed a protective effect against in-hospital mortality (IHM) throughout the study period

  • Diabetes has a protective effect on IHM among HIV-infected patients

Read more

Summary

Introduction

HIV treatment has improved substantially since the introduction of combination antiretroviral therapy (cART). The subsequent improvement in life expectancy has been characterized by an aging HIV-infected population who are increasingly affected by age-related noncommunicable diseases [1,2]. Associated comorbidities frequently include metabolic complications that increase the risk of diabetes mellitus. The prevalence of diabetes among HIV-infected patients has been reported to be between 2% and 14% [3,4,5] and is expected to continue to increase in aging HIV-infected patients. HIV-infected patients may be at increased risk of developing diabetes as a result of viral coinfection and adverse effects of treatment [6,7]. Previous studies have reported a wide spectrum of metabolic alterations associated with cART, including changes in glucose homeostasis and fat redistribution [8,9]. Given that the insulin resistance and impaired glucose tolerance induced by cART might act as a precursor of diabetes, the risk of diabetes could have increased in the cART era

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call